ABSTRACT
The nasal route of drug delivery is convenient for administering active pharmaceutical agents. These agents can be for local therapy (e.g., established treatments such as corticosteroids for rhinitis) or for systemic therapy [e.g., migraine therapies such as Imigran1 (U.K.)/Imitrex1
(U.S.)]. Table 1 summarizes a range of aqueous nasal productsmarketed in the United States and the United Kingdom. The numbers of active ingredients are relatively small, and comprise both simple low molecular mass molecules and newer peptide molecules.
